Seattle Tech Week returns July 27-31, and litigation risk is one topic we hear about from growing companies. The data below shows why litigation preparedness belongs next to product and fundraising strategy, not behind it.

The Q1 2026 Venture Beacon report shows that fundraising activity recovered through 2025 and into Q1 2026, with total capital rising meaningfully from 2023 lows.

For many companies building in New York, the challenge isn’t growth itself. It’s how quickly operational, governance, regulatory, and litigation issues start to matter once that growth accelerates.

The Game Developers Conference 2026 brought more than 20,000 developers, publishers, investors, and platform stakeholders to San Francisco this year.

Artificial intelligence remained the defining theme of 2025, shaping both the scale and direction of capital flows.

Among all funding stages, Series C emerged as the breakout performer of 2025.

After years of volatility, 2025 signaled a pivotal moment for the venture capital market.

Client trust goes hand in hand with a strong data privacy program.

Government shutdowns are becoming a more persistent threat; is your IPO ready?

As life sciences companies mature, intellectual property often becomes both their most valuable and most scrutinized asset.

As early-stage life sciences companies prepare for their next financing or partnership, intellectual property due diligence is often the first, and most consequential, checkpoint.